Aligos Therapeutics Inc (ALGS): Insights At A Glance

The Vanguard Group, Inc. has recently announced that it has increased stake in Aligos Therapeutics Inc (NASDAQ:ALGS) by 2.29%. After grabbing 1.01 million shares, the institutional investor is now in possession of 22600.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 2.50% having worth around $0.61 million. Moreover, Newtyn Management LLC increased its share by 20000.0 to have a control over 0.92 million shares.

Aligos Therapeutics Inc (ALGS) concluded trading on 12/07/23 at a closing price of $0.65, with 2.19 million shares of worth about $1.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -40.91% during that period and on Thursday the price saw a loss of about -4.69%. Currently the company’s common shares owned by public are about 39.83M shares, out of which, 32.02M shares are available for trading.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


Sponsored

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the ALGS stock and their offered price forecasts bring an average price target of $4.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.00 and could fall to a lowest price of $1.00. The stock’s current price level is 83.75% above of average price target set by the analysts, while a rise to estimated low would result in gain of 35.0% for the stock. However, touching the estimated high of $7.00 would mean a gain of 90.71% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 3 times over the past 12 months. They bought 8,726,961 shares in 3 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Aligos Therapeutics Inc Vanguard Total Stock Market ETF is currently holding 0.71 million shares of worth totaling $0.43 million. The company recently came buying 0.0 shares which brought its stake up to 1.76% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after selling 0.14 million shares, have now control over 0.35% of the stake in the company. It holds 15317.0 shares of worth $85323.0.

Aligos Therapeutics Inc (NASDAQ: ALGS) started trading at $0.6401, below -$0.04 from concluding price of the previous day. However, the stock later moved at a day high price of 0.6916, or with a loss of -4.69%. Stock saw a price change of -7.14% in past 5 days and over the past one month there was a price change of -11.68%. Year-to-date (YTD), ALGS shares are showing a performance of -31.79% which decreased to -27.82% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.54 but also hit the highest price of $2.41 during that period. The average intraday trading volume for Aligos Therapeutics Inc shares is 81.46K. The stock is currently trading -4.73% below its 20-day simple moving average (SMA20), while that difference is down -8.21% for SMA50 and it goes to -32.60% lower than SMA200.

The Vanguard Group, Inc. acquired 1.01 million shares of Aligos Therapeutics Inc having value of about $0.61 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 22600.0 shares in the company valued at close to $14690.0, or have control over 2.29% stake in the company. Aligos Therapeutics Inc (NASDAQ: ALGS) currently have 39.83M outstanding shares and institutions hold larger chunk of about 25.50% of that. Holding of mutual funds in the company is about 43.71% while other institutional holders and individual stake holders have control over 44.83% and 3.58% of the stake respectively.

The stock has a current market capitalization of $48.70M and its 3Y-monthly beta is at 2.22. It has Quick Ratio of 3.32 while making debt-to-equity ratio of 0.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALGS, volatility over the week remained 10.92% while standing at 13.62% over the month.

Analysts are in expectations that Aligos Therapeutics Inc (ALGS) stock would likely to be making an EPS of -$0.28 in the current quarter, while forecast for next quarter EPS is -$0.39 and it is -$0.96 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.43 which is -$0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.51 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 38.22% while it is estimated to increase by 31.29% in next year.

Analysts at 2 brokerage firms have issued recommendations for the Aligos Therapeutics Inc (ALGS)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 2 Wall Street analysts, 1 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on January 06, 2023 offering an Overweight rating for the stock and assigned a target price range of between $2 and $3 to it.

Most Popular

Related Posts